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ABSTRACT 
Bilirubin is the degradation product of heme, the 
bulk of which is derived from hemoglobin of senescent 
erythrocytes and hepatic hemoproteins. Bilirubin is 
potentially toxic, but is normally rendered harmless by 
binding to plasma albumin, and efficient hepatic clearance. 
Jaundice, (also known as icterus) is a yellowish 
pigmentation of the skin, the conjunctival membranes over 
the sclerae (whites of the eyes), and other mucous 
membranes caused by hyperbilirubinemia (increased levels 
of bilirubin in the blood). Complications of jaundice 
include sepsis especially cholangitis, biliary cirrhosis, 
pancreatitis, coagulopathy, renal and liver failure. 
Treatment of rats with Phenylhydrazine 5 mg/ kg body 
weight for five days resulted in the development of 
jaundice as BR level was found to be higher than 2 mg/dL. 
Bilirubin lowering potential of Benzoin ethyl alcohol 
extract was evaluated in temporarily jaundiced adult 
wistar rats. Treatment of these rats with Benzoin extract 
for seven days reduced the BR level significantly to the 
normal value. Whereas smaller dose (10mg/kg body 
weight) resulted in the reduction in BR level from 2.51 ± 
0.02 to 0.90 ± 0.01 mg/dL, higher doses of 20 and 40 
mg/kg body weight were found to be more effective in 
reducing the bilirubin level from 2.54 ± 0.01 to 0.82 ± 
0.01 mg/dL and from 2.49±0.02 to 0.66±0.01 mg/dL, 
respectively. Therefore, Benzoin ethyl alcohol extract can 
be used to reduce bilirubin concentration to a normal level 
in jaundiced subjects. 
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Bilirubin (from the Latin ``bilis,'' meaning bile, 
and ``rubor,'' meaning red) is a bile pigment formed during 
the catabolism of heme-containing compounds, primarily 
hemoglobin. Excessive accumulation of bilirubin, as a 
result of enhanced production or impaired elimination, 
results in yellow discoloration of the skin, sclera, and 
mucus membranes, which is termed jaundice1.The 
management of severe unconjugated hyperbilirubinemias, 
including pathologic neonatal jaundice or that 
accompanying Crigler-Najjar (CN) disease, remains a 
clinical problem2. Several therapeutic approaches are 
available for the treatment of severe unconjugated 
hyperbilirubinemias, including phototherapy or exchange 
transfusions. However, these therapeutic options are 
costly, time-consuming and potentially risky3, 4. New 
efficient methods to decrease elevated serum bilirubin 
levels would be greatly appreciated. Prevention of 
bilirubin production results from any form of haemolysis, 
facilitation of glucuronyl transferase; the enzyme that 
converts bilirubin into a polar, water-soluble glucuronide, 
Prevention of enterohepatic circulation of bilirubin via 
enhancement of bilirubin sequestration or degradation in 
the intestinal lumen in newborn infants, patients with 
hereditary hyperbilirubinemias or those with bile salt 
malabsorption predisposing to pigment cholelithiasis is an 
alternative approach to these standard methods. The use 
of natural products with therapeutic properties is as 
ancient as human civilization and, for a long time, mineral, 
plant and animal products were the main sources of 
drugs5.In recent years, there has been growing interest in 
alternative therapies and the therapeutic use of natural 
products, especially those derived from plants6. Benzoin a 
resin from Styrax tonkinensis (Benzoin Siam) and Styrax 
benzoin (Benzoin Sumatra) species locally known as 
Sambrani is a popular traditional medicine. Siam benzoin 
gum has previously been described as containing coniferyl 
benzoate (65-75%), p-coumaryl benzoate (10-15%), 
cinnamyl cinnamate (0.5-6%), benzoic acid (12%), vanillin 
(0.3%), and siaresinolic acid (6%) 7, 8, 9, 10, 11. Externally; 
Benzoin possesses antiseptic & stimulant properties. 
Internally; it has carminative, antiseptic, expectorant & 
diuretic properties12, 13. People without access to modern 
medicine rely on these for the treatment of 
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Although Benzoin is known traditionally for curing 
jaundice, no scientific study has been carried out on 
Benzoin for checking its BR lowering action. In this study, 
BR clearing potential of Siam Benzoin ethyl alcohol 




MATERIALS AND METHODS 
 
To prepare the Siam Benzoin ethyl alcohol 
extract, 400gms of Benzoin lumps were broken into small 
pieces and ground to powder form in a ball mill. Then the 
powder was treated with ethyl alcohol (2 L) at 50-60°C for 
8 h14. The mixture was filtered in batches of 200 ml 
through a muslin cloth and subjected to evaporation to get 
the brownish black mass as extract. About 42 g of ethanol 
extract with a yield of 10.2% (w/w) was obtained. It was 
stored in a capped bottle at 25°C. For preparation of 
different doses, desired quantity of ethanolic extract was 
dissolved in 0.9% sodium chloride solution15.  
 
Animals 
Wistar adult rats weighing 180-200 g of either 
sex were used in the study. The animals were maintained 
in colony cages at 25±2 oC, relative humidity 50-55% 
maintained under 12:12 h light and dark cycle. The 
animals were fed with Standard animal feed (Hindustan 
Lever Ltd. Bangalore, India) and water; animals were 
acclimatized to the laboratory conditions for 5 days prior 
to experimentation. All experiments were carried out 
according to the guidelines for care and use of 
experimental animals, and are approved by Committee for 
the Purpose of Control and Supervision of Experiments on 
Animals (CPCSEA). Study proposal was approved by the 
Institutional Animal Ethical Committee.  
Bilirubin letting down activity 
Wistar adult rats weighing 180-200 g were 
treated with Phenylhydrazine 5 mg/ kg body weight. I.p. 
(PHZ) for five days to develop jaundiced condition 
following standard procedure16 with slight modification. 
PHZ solution was prepared by mixing 100 mg of PHZ 
with 10 ml of 0.01 M sodium phosphate buffer, pH 7.4 
containing 0.138 M NaCl. Each animal received PHZ 
solution at a dose of 5 mg/ kg body weight) as a single 
dose through intraperitoneal route for five consecutive 
days. The concentration of total serum BR was determined 
by Fog’s method both prior (on 1st day) and after PHZ 
treatment (on 5th, 6th, 7th, and 8th days). Measurement of 
BR in the animal sera after 5 doses of PHZ confirmed the 
jaundiced condition. The treatment of jaundiced rats with 
Benzoin ethanolic extract (orally; once a day) was started 
6 h after the last injection of PHZ. Animals were divided 
into four groups each consisting of six rats. The first 
group (I) did not receive any treatment and served as 
control.  The other three groups (II, III and IV) of rats 
were treated with 10 mg (lower range), 20 mg (medium 
range) and 40 mg (higher range) of Benzoin ethanolic 
extract respectively per kg body weight. No gross change 
in behavior of the animals was observed at these doses. 
Blood was collected from the tail of the rats on the first 
(normal) day, fifth day (after 6 h of PHZ treatment) and 
the following four (6th , 7th, and 8th) days after Benzoin 
ethanolic extract administration to determine the BR 
concentration. Since BR level became approximately 
normal on 8th day using three different doses of Benzoin 
ethanolic extract, the study was conducted up to 8days. 
Statistical analysis 
The results were reported as mean ± SEM. 
Differences in means were estimated by means of ANOVA. 
The mean values of the results from the control group 
were compared to the mean values of groups treated with 
extract using the (Dunnett post hoc test). The results 
were considered significant at P < 0.05. 
 
RESULTS AND DISCUSSION 
 
Group I represents the control group; while 
group II, III and IV represent other three groups which 
received Benzoin treatment with a dose of 10, 20 and 40 
mg/kg body weight respectively (Table-1). 
On 1st day of the study before PHZ treatment, BR level of 
rats in these groups was found in the normal range (0.39 ± 
0.03 to 0.40 ± 0.02 mg/dL). Treatment of these rats with 
PHZ for five days resulted in the development of jaundice 
as BR level was found to be higher than 2 mg/dL in all 
four groups, falling in the range of 2.49 ± 0.02 to 2.54 ± 
0.01 mg/dL. There was no significant difference in the BR 













Table 1: Effect of Benzoin extract on total serum bilirubin level 
 Total serum Bilirubin level (mg/dL) 
Group Treatment Day 1 Day 5 Day 6 Day 7 Day 8 












0.40±0.02 ns 2.49±0.02 ns 1.84±0.01** 1.15±0.01** 0.66±0.01** 
The results given are mean ± S.E.M; number of animals used (n=6) **P < 0.01 and   *P < 0.05 was considered as 
significant in comparison to control 
 
As can be seen from (Table -1) the 
concentration of BR (mg/dL) in control group rats 
receiving PHZ treatment but without any extract 
treatment the BR concentration increased from             
0.39 ± 0.03 to 2.52 ± 0.02 mg/dL on the fifth day upon 
PHZ treatment. The serum BR level was reduced to 1.82 
± 0.02 mg/dL in the next three days if no further 
treatment was given to these rats. However, this 
concentration of BR was still higher than the normal value 
suggesting prevalence of the hyperbilirubinemic condition 
up to nine days.  The effect of three different doses of 
Benzoin extract treatment on the serum BR level of 
jaundiced rats is shown in       (Table-1). Benzoin extract 
treatment with a dose of 10mg/kg body weight for three 
consecutive days reduced the serum BR level of jaundiced 
rats from 2.51 ± 0.02 on day 5 to 0.90 ± 0.01 mg/dL on 
day 8. This decrease in BR level was highly significant (p 
<0.01) compared to jaundiced condition. A selection of a 
higher dose (20 mg/kg body weight) of Benzoin ethanolic 
extract was found to be more successful in reducing the 
BR level of jaundiced rats significantly (p <0.01) from 2.54 
± 0.01 on day 5 to 0.82 ± 0.01 mg/dL on day 8. A 
Selection of a still higher dose (40 mg/kg body weight) 
reduced the BR level from 2.49±0.02 on day 5 to 
0.66±0.01 on day 8 which was highly significant (p 
<0.01).Exposure to Phenylhydrazine cause damage to red 
blood cells, potentially resulting in anemia and 
consequentially   hyperbilirubinemia17. PHZ increases 
reactive oxygen species (ROS). ROS production was 
associated with extensive binding of oxidized and 
denatured haemoglobin to the membrane cytoskeleton. 
Thus, PHZ-induce haemolytic injury seems to be derived 
from oxidative alterations to red blood cell proteins. 18  
 
All these results suggest that Benzoin ethanolic 
extract has the potential to reduce BR concentration to a 
normal level in jaundiced rats. The possible mechanisms of 
BR reducing action of Benzoin ethanolic extract might be 
the increased activity of glucuronyl transferases19 to 
facilitate hepatic conjugation of BR or increased BR 
binding by albumin20 or Prevention of enterohepatic 
circulation of bilirubin via enhancement of bilirubin 
sequestration or degradation in the intestinal lumen21 or 
probably due to a shift in the distribution equilibrium of 
the pigment between serum, skin and other tissues or 
some other mechanism which may be attributed to its 
benzoic acid content22,23. Therefore, Benzoin ethanolic 
extract can be used successfully to develop a future drug 
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